t3: absolute LVEF reduction −8.3%, CI −15.88 to −0.72, p = 0.005) compared to IDH1/2wildtypeAML patients (Fig. 4a and Supplementary Table S5 in the Data Supplement), indicating that the IDH2 mutation status in AML patients is associated with impaired left ventricular ejection fraction during AML therapy, which is independent of measured baseline covariates. Here, IDH2 is linked to acute myeloid leukemia.